Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
May 15th 2008Drug InformationSleep / Sleep Disorders
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced positive results from a Phase 1 clinical trial of AZ-007 (Staccato(R) zaleplon). AZ-007 is an inhalation product candidate being developed for the treatment of insomnia patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
